Convincing lines of evidence in both mice and humans show that exaggerated T follicular helper (Tfh) responses is pathogenic in autoimmune diseases. However, the cause of exaggerated Tfh response in humans is still much less clear than in mouse models where genetic factors can be manipulated for in vivo testing. Nonetheless, recent advances in our understanding on the mechanisms of human Tfh differentiation and identification of multiple risk loci in genome-wide association studies have revealed several pathways potentially associated with exaggerated Tfh response in human autoimmune diseases. In this review, we will first briefly summarize the differentiation mechanisms of Tfh cells in humans. We describe the features of "Tfh-like" cells recently identified in inflamed tissues of human autoimmune diseases. Then we will discuss how risk loci identified in GWAS are potentially involved in exaggerated Tfh response in human autoimmune diseases.
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T follicular helper cells and their precursors are endowed with features to perform these tasks (1) (2) (3) (4) . After interacting with antigen-presenting dendritic cells (DCs) in T cell-rich area of secondary lymphoid organs, Tfh precursors increase the expression of the chemokine receptor CXCR5 and the G protein-coupled receptor S1PR2, while decreasing the expression of CCR7 and the selectin ligand PSGL1. These changes in the cell surface molecular profile are required for their migration toward and retention within B cell follicles enriched with the chemokine CXCL13. Tfh cells produce + T cells receive signals via three major receptor families: the T cell receptor (TCR, signal 1), receptors for co-stimulatory molecules (signal 2), and receptors for cytokines (signal 3). For signal 1, evidence in both mice and humans shows that strong TCR signals promote Tfh cell differentiation. For signal 2, in addition to CD28 signals which is essential for optimal T cell activation, signals via inducible co-stimulator and Ox40 promote human naïve CD4 + T cells to express multiple Tfh molecules. For Signal 3, among inflammatory cytokines that activated DCs produce, IL-12 and IL-23 play dominant roles for human naïve CD4
+ T cells to express Tfh molecules. The effect of IL-12 and IL-23 is further enhanced by the co-presence of TGF-β family molecules, TGF-β and Activin A. Given that TGF-β and Activin A are often highly expressed in human inflamed tissues, the source of these cytokines might be both from interacting DCs and from microenvironment. The surface markers commonly used to define human GC Tfh cells and their precursors in lymphoid organs are CXCR5, ICOS, and PD-1. GC Tfh cells express these molecules at high levels, whereas their precursors express at low levels ( Table 1) . CD127 and CCR7 are expressed by Tfh precursors, but not by GC Tfh cells (7) . The combination of CXCR5 and PD-1 is often used to define GC Tfh cells and their precursors also in mice, but ICOS can be broadly expressed by activated CD4 + T cells in lymphoid organs (8) and is rarely used to define mouse GC Tfh cells.
Prolonged Tfh response results in enhanced generation of mature Tfh cells and/or extrafollicular helper cells, and eventually leads to autoimmunity (3, 4) . This is convincingly demonstrated in many autoimmune-prone mouse models including Roquin san/ san mice, in which CD4 + T cells overexpress ICOS and excessive signals through ICOS cause exaggerated Tfh and GC responses (9) . Molecular mechanisms for Tfh cell differentiation and the causal link of genetic mutations to exaggerated Tfh responses are relatively well defined in mice (3, 4) . However, less is known for human autoimmune diseases. In this review, we will first summarize the differentiation mechanisms of Tfh cells in humans briefly. We will also summarize the features of pathogenic "Tfh-like" cells recently characterized in inflamed tissues of human autoimmune diseases. Last, we will discuss how risk loci identified in GWAS overlap with Tfh-differentiation pathway and how they are potentially associated with exaggerated Tfh response in human autoimmune diseases.
DiFFeRenTiATiOn OF Tfh CeLLS in HUMAnS
When interacting with antigen-presenting DCs, naïve CD4 + T cells receive signals via three major receptor families, which ultimately determine the fate of T cell differentiation: the T cell receptor (TCR, signal 1), receptors for co-stimulatory molecules (signal 2), and receptors for cytokines (signal 3). Recent studies show that each signal provides parameters that negatively and positively affect Tfh differentiation in humans and mice (Figure 1 in vitro induces human naïve CD4 + T cells to express higher levels of multiple Tfh molecules, including CXCR5, Bcl6, IL-21, and Ox40 (11) . As demonstrated in experimental mouse models (8, 10) , it is possible that human Tfh cell clones display relatively higher TCR affinity than non-Tfh cell clones, yet this remains to be tested.
Signal 2: Co-Stimulatory Molecules
Inducible co-stimulator is critically involved in Tfh cell biology at multiple levels, including the differentiation program at early stages (12, 13), their migration into B cell follicles (14) , and the functions when interacting with B cells (15, 16 
Signal 3: Cytokines
In humans, IL-12 produced by DCs is the major DC-derived cytokine driving human naïve CD4
+ T cells to become Tfh-like cells (20) (21) (22) (23) (24) . This is in contrast to mouse CD4 + T cells which acquire multiple features of Tfh cells in response to IL-6 and IL-21 (25, 26). Children who lack the expression of functional IL-12 receptor β1 chain, a common receptor for IL-12 and IL-23, display less Tfh cells and memory B cells in blood circulation and impaired GC formation in lymph nodes, providing in vivo evidence of the significance of this pathway for intact Tfh response in humans (21) . Another important set of cytokines for human Tfh cell differentiation is TGF-β family cytokines TGF-β and Activin A, which activate the Smad signaling pathways including Smad2 and Smad3. Although only marginally effective by themselves, TGF-β and Activin A co-operate with IL-12 and IL-23 to promote human naïve CD4 + T cell differentiation toward the Tfh lineage (23, 27) . TGF-β signals render STAT4 and STAT3 (activated by IL-12 and IL-23) to promote human naïve CD4 + T cells to acquire Tfh gene signature, while suppressing Th2 and regulatory T cell gene signatures (23) . Furthermore, both TGF-β and Activin A also induce human CD4 + T cells to produce CXCL13 (27, 28), the major chemokine that human mature Tfh cells produce (7) . TGF-β and Activin A are often strongly expressed in inflammatory sites, such as synovial fluid in rheumatoid arthritis (RA) (29, 30). Of note, neither TGF-β nor Activin A, even in the presence of Tfh-promoting cytokines, such as IL-6 and IL-21, induces Tfh molecules in mouse CD4 + T cells, and, therefore, this pathway is not shared in mice (23, 27) .
Several cytokines are known to inhibit human Tfh cell differentiation. Type I (IFN-α, β, and ω) and type III (IFN-λ1 and λ2) interferons are potent inhibitors of Tfh cell differentiation in humans, and strongly diminish the expression of Tfh markers and gene signature by human naïve CD4 + T cells (23) . This suggests that exaggerated Tfh cell responses in human autoimmune diseases with dominant IFN signature, such as systemic lupus erythematosus (SLE), is not mediated by the direct effect of type I IFNs on T cells, but by an indirect effect on APCs. Type I IFNs promote human DCs to produce Tfh-promoting cytokines, such as IL-12, IL-23, and IL-6 (31). Similarly, mouse studies demonstrated that type I IFN signals act as an adjuvant for antibody responses by promoting DCs to produce IL-6 (32, 33).
In mice, the IL-2-STAT5-Blimp1 axis inhibits Tfh cell differentiation at multiple differentiation stages (34, 35), and deprivation of IL-2 signals in the microenvironment is important for Tfh cell differentiation (36). There is evidence that IL-2 suppresses also human Tfh cell differentiation. IL-2 inhibition by a neutralizing Ab increased CXCR5 expression by human naïve CD4
+ T cells cultured in Tfh-promoting culture conditions in vitro (27). Furthermore, treatment with low dose IL-2 decreased CXCR5
+ PD-1 + CCR7 lo cTfh cells in SLE accompanied with marked decrease of disease activity (37). It is of note, however, that it is unclear whether decrease of disease activity was dependent on decreased Tfh activity and whether decreased Tfh activity was the primary effect of IL-2 on Tfh cells. Current evidence highly suggests that the major target of low dose IL-2 treatment was Tregs. Low dose IL-2 treatment selectively induced STAT5 activation in Tregs but not conventional CD4 + T cells in vitro (38). In chronic GVHD patients, low dose IL-2 expanded circulating Treg frequency and their suppressive functions (38, 39). Therefore, it is possible that decrease of Tfh activity was secondary to increased activity of Tregs. suggest that the precise nature of B helper T cells associated with autoantibody production in inflamed tissues might differ among diseases, likely reflecting the differences in microenvironment. The chemokine receptors and integrins expressed by these "Tfh-like" cells might be critically involved for their migration to and retention in inflammatory tissues. It will be important to clarify how the developmental mechanisms and the functional regulations of "Tfh-like" cells are different from Tfh cells in lymphoid organs.
TRAnSCRiPTiOn FACTOR neTwORK in Tfh CeLL DiFFeRenTiATiOn CD4 + T cell differentiation is controlled by transcription factors which govern the expression of a set of target genes. Recent studies in mice identified a number of transcription factors and pathways that affect Tfh cell differentiation. Transcription factors positively regulate Tfh cell differentiation include Bcl6, Ascl2, Batf, cMaf, IRF4, STAT3, STAT1, STAT4, NOTCH1, NOTCH2, Tcf1, and Lef1 (42) (43) (44) (45) (46) (47) (48) . Among these, Bcl6 is specifically required for the differentiation of Tfh cells, but not other CD4 + T cell subsets (7, 44, (49) (50) (51) . The transcription factor Blimp-1, an antagonist of Bcl6, inhibits Tfh cell differentiation (51) . Genome-wide analysis of Bcl6-binding sites by using ChIP-Seq demonstrated that Bcl6 binds to genes associated with the differentiation of other CD4 + T cell lineages, including Th1, Th2, Th17, and Tregs, and genes that negatively affect CD4 + T cell localization in GCs (52) . Thus, Bcl6 primarily acts as a repressor to inhibit the differentiation toward other CD4 + T cell lineages and to diminish the molecules that exclude CD4 + T cells from GCs (49-52). Interestingly, many genes repressed by Bcl6 contained AP1 and STAT motifs but lacked Bcl6 motif, suggesting that AP1 and STAT recruit Bcl6 to the target sites and repress the target genes (52).
RiSK LOCi iDenTiFieD in gwAS OF AUTOiMMUne DiSeASeS AnD THeiR POTenTiAL ASSOCiATiOn wiTH eXAggeRATeD Tfh ReSPOnSe
The genome-wide association studies (53) are an experimental design used to detect associations between genetic variants and traits including diseases in samples from populations (54) . GWAS in autoimmune diseases have successfully identified loci associated with an increase or a decrease of risk (53) (54) (55) . A fraction of the identified risk loci is located within or in the proximity of genes encoding transcription factors and cell surface molecules expressed by T cells and/or antigen-presenting cells. How risk haplotypes are associated with their dysregulated function and linked to the immunological consequences largely remains to be established. Nonetheless, several key risk loci are located in the proximity of genes that regulate Tfh differentiation in humans, and thus might contribute to the exaggerated Tfh response in human autoimmune diseases. Here we focus on three genes, STAT4, IRF5, and TNFSF4, which are identified and validated as risk loci in GWAS in multiple autoantibody mediated autoimmune diseases with a strong disease association at the genome-wide p value of at least 5 × 10 −8 (Figure 2 ).
STAT4
STAT4 is among the top risk loci (other than HLA genes) identified in GWAS on SLE, RA, and Sjogren's syndrome (56) . STAT4 is dominantly activated by IL-12 and to a lesser extent by IL-23 and type I IFNs (57). As discussed above, the IL-12-STAT4 pathway strongly promotes Tfh cell differentiation in humans. Human naïve CD4 + T cells primed in the presence of IL-12 highly upregulate expression of multiple Tfh molecules (21, 58) , which are inhibited by decreasing STAT4 expression by specific siRNA transfection (22, 23 (60, 61) .
A recent report showed that ustekinumab, a human recombinant antibody against IL-12p40 (a component of IL-12 and IL-23), was effective for active SLE in a phase II trial (presented in ACR 2017 meeting). Although this encouraging outcome remains to be confirmed, it is of great interest to determine whether the treatment with ustekinumab reduced Tfh responses, and more importantly whether the reduction of Tfh response correlated with the improvement of clinical parameters. Alternatively, treatment with ustekinumab might target other immune cells including Th1 and Th17 cells, which are also proposed to play pathogenic roles in SLE (62, 63) . Determining the mode of action of ustekinumab will provide critical insights into the type of pathogenic CD4 + T cells and the pathways in SLE. Other STAT molecules STAT3 and STAT1 also positively regulate Tfh cell differentiation in mice (4). STAT3 is also critical for human Tfh cell differentiation, as patients with STAT3 LOF mutations as well as patients with IL-21 receptor deficiency display significantly less cTfh cells (64) . Furthermore, CD4 + T cells from patients with STAT3 LOF mutations and IL-21 receptor deficiency produce substantially less IL-21 upon IL-12 stimulation (24) , suggesting that the IL-21-STAT3 axis is critical for enhancement of IL-21 expression. Interestingly, despite less IL-21 production, STAT3 LOF human CD4 + T cells stimulated with IL-12 express normal levels of CXCR5, ICOS, and Bcl-6 (26). Thus, STAT3 and STAT4 might differently contribute to the expression of each Tfh molecule in human CD4 + T cells, and IL-21 expression might be more dependent on the IL-21-STAT3 axis than the expression of CXCR5, ICOS, and Bcl-6. In this line, it is likely that decreased cTfh cells in STAT3 LOF are also due to severely impaired B cell response. STAT3 LOF display significantly less memory B cells (65) , and the differentiation of STAT3 LOF B cells into plasmablast is severely impaired due to failure to respond to IL-6, IL-10, or IL-21 (65) . Notably, unlike STAT4, STAT3 has been identified as risk loci in GWAS in autoinflammatory diseases, such as multiple sclerosis, Crohn's disease, and ulcerative colitis, which are less dependent on autoantibodies (53) . STAT1 signals seems to play less significant roles in Tfh cell differentiation in humans than in mice, as patients with both STAT1 LOF and gain-of-function (GOF) mutations display normal frequency of cTfh cells (24, 58, 64) . No GWAS on autoimmune diseases have identified STAT1 as a risk allele. These observations suggest that genetic variants of STAT1 and STAT3 do not contribute much to pathogenic Tfh and GC responses in autoimmune diseases. However, this notion does not preclude the involvement of STAT3 mutations in human autoimmune diseases. Patients with STAT3 GOF mutations show massive multiorgan autoimmunity, autoimmune cytopenia, lymphoproliferation, and immunodeficiency, likely due to impaired Treg differentiation and functions (66) (67) (68) . Whether STAT3 GOF increases Tfh response or not is currently unclear. However, many patients display hypogammaglobulinemia (68) , and thus that autoimmunity in STAT3 GOF seems to be caused by dysregulation of antibody response rather than a general increase of Tfh response.
iRF5
IRF5 is another transcription factor whose haplotype is highly associated with an increased risk of SLE, RA, and Sjogren's syndrome (53) . IRF5 is expressed by a broad range of APCs, including monocytes, macrophages, DCs, plasmacytoid DCs, and B cells, and is critically involved in the production of inflammatory cytokines, including IL-12, IL-23, IL-6, and type I IFN (69) (70) (71) . These cytokines are enriched in inflamed tissues in autoimmune diseases, and such inflammatory cytokine milieu causes a positive-feedback loop for the expression of IL-12 and IL-23 by promoting the generating M1 macrophages that highly express IRF5 (69). Thus, it is possible that IRF5 risk haplotype is linked to the enhanced production of Tfhpromoting cytokines in subjects with autoimmune diseases traits. IRF5 is required in normal human B cell proliferation and differentiation into plasmablasts (72) , and therefore, IRF5 risk allele may also intrinsically affect B cells. The importance of IRF5 for lupus pathogenesis was also demonstrated by the attenuation of the disease in mouse models deficient of IRF5, which was accompanied with decreased activated CD4 + T cells and autoantibodies (73, 74) .
TNFSF4
TNFSF4 encodes Ox40L, a TNF ligand family molecule that delivers signals promoting human Tfh cell differentiation (11) as described earlier. TNFSF4 has been identified as another prominent risk allele in SLE and RA (53) . In active SLE, blood CD14 + monocytes and tissue CD11c + myeloid cells upregulate the expression of Ox40L (11) . TNFSF4 risk allele might enhance signals via Ox40 and contribute to enhanced Tfh responses. The importance of the Ox40-Ox40L axis for antibody response (75) (76) (77) and autoimmune disease was also demonstrated in studies with mouse models (18, 78, 79) . TNFSF4 is also found as a risk allele in GWAS on allergies, such as asthma, hay fever, and eczema; an observation consistent with the importance of Ox40-Ox40L pathway for Th2 response (80) .
In contrast, it is somewhat surprising that ICOS, another key co-stimulatory molecule for Tfh cell differentiation in humans and mice, and its ligand ICOS-ligand (encoded by ICOSLG) are not among the risk loci identified in GWAS on autoantibody mediated autoimmune diseases. ICOSLG was instead found to be highly associated with Crohn's disease and ulcerative colitis (53 
COnCLUDing ReMARKS
Although the mode of actions remains to be established, a positive outcome of ustekinumab in active SLE patients provides a new proof of principle that T cells can be a therapeutic target for autoantibody-mediated autoimmune diseases. Another evidence came from a clinical trial performed some 15 years ago with anti-CD40L (BG9588) on lupus nephritis. Although the trial was prematurely terminated due to the development of thrombotic events and associated fatality in some patients, the early results were encouraging and the treatment reduced serum anti-dsDNA titers, increased serum complement levels, and reduced nephritis score (81) . Thus, targeting B helper T cells can be beneficial for treatment of autoimmune diseases. It will be important to define the differentiation mechanisms and the functions of Tfh and Tfh-like cells that directly contribute to the production of autoantibodies in lymphoid organs as well as inflamed tissues. Determining how risk loci in autoimmune diseases are associated with the molecular mechanisms for exaggerated Tfh responses is also of great importance. These studies will enhance our understanding in human autoimmune diseases and also might provide novel therapeutic targets.
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